Anti-PD-1/PD-L1 treatment has displayed a wide spectrum of antitumor activity across various tumors, and several anti-PD-1/PD-L1 agents have demonstrated clinical efficacy and manageable tolerance in patients with NSCLC. This evidence concerns the gene CD274 and non-small cell lung carcinoma.